Everything below concerns preclinical models. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Evidence from reviews of benzodiazepine tolerance mechanisms and clonazepam use in psychiatric disorders contrasts with clinical guidelines that benzodiazepines lose anxiolytic efficacy over weeks; these reviews present RCT evidence of continued anxiolytic efficacy at up to 22 weeks and observational (open-label) evidence of continued efficacy at up to 3 years. A 2015 review found a larger effect with medications than with talk therapy. Medications with benefit include serotonin-noradrenaline reuptake inhibitors, benzodiazepines, and selective serotonin reuptake inhibitors.
=== 2025 elections === On October 5, 2024, Duterte announced that he will run for mayor of Davao City, with his son, incumbent Mayor Sebastian Duterte, as his running mate for vice mayor in 2025. He also rejected calls for him to run for senator, citing his old age. Duterte officially filed his candidacy on October 7; however, on November 7, he welcomed the candidacy of his former cabinet secretary, former Civil Service Commission chairperson Karlo Nograles as Davao City mayor, adding he is retired and wishes to give the position to the next generation. In May 2025, Duterte was elected as mayor despite his detention at The Hague by the ICC. However, he was unable to take his oath on the start of his term on June 30, 2025, due to his imprisonment. As a result, his son Sebastian, who was elected vice mayor, became acting mayor. On January 23, 2026, Sebastian was sworn in as mayor of Davao City, following his father's failure to take the oath of office within the six-month prescribed period due to his detention.
=== Cancer diagnosis and departure === In the serial's first episodes of 2022, Ari takes the blame for Matthew's murder in order to protect Mia and Chloe. Ari is held on remand ahead of his sentencing hearing. Kipa-Williams explained that none of the Parata family can accept that Ari is going to prison. But he cannot accept seeing Chloe or Mia go there either, and he cannot work out a way where it would end well for them. Kipa-Williams continued, "He decides to take the fall because he knows he can handle it." Tane steps up as head of the family in Ari's absence, while Nikau pleads with his uncle to tell the police the truth. Kipa-Williams believed that his character's one regret was not marrying Mia. The storyline marked the beginning of Ari's exit from Home and Away, as he is later rushed to hospital with stabbing pains. Logan Bennett (Harley Bonner) initially thinks he may have appendicitis, but he later informs Ari that he has cancer of the appendix, which has spread to his abdomen. Logan also tells Ari that he could undergo a large, lengthy surgery to remove the tumours, but it would need to be repeated every few months. Ari decides not to go through with surgery as he wants to die on his terms. Daniel Kilkelly of Digital Spy reported that rumours of Kipa-Williams' exit from the serial had been circulating for months. Mia makes a "moving" proposal that she and Ari get married at the hospital, which he accepts. Ari insists that the day is about "celebration, not commiseration", and he and Mia marry in front of Tane, Nikau, and Chloe.
Sources: en.wikipedia.org
=== Japan, South Korea === Japan, which had permitted its feed additive use at least until 2009, and South Korea only allow import of meat with ractopamine residues up to the maximum residue limit (MRL), but do not permit its use in beef production.
=== 23 May === In its evening report, the Ukrainian military reported that there were 25 air strikes and 20 incidents of shelling reported across the country for the day, but no missile attacks. Yevgeny Prigozhin, head of the Wagner Group, promised to transfer control of the Ukrainian city of Bakhmut to the Russian army by 1 June. In an interview, he said that more than 20,000 of his fighters died in the battle for the city, and acknowledged that the Russian military had killed civilians. President Zelenskyy visited naval infantry troops along the Vuhledar-Maryinka defence line in Donetsk Oblast as part of commemorations of the Day of the Ukrainian Marines. He announced that new marine brigades would be added to the Ukrainian military's existing units. The governor of Donetsk Oblast said Russian aerial bombs struck Toretsk, damaging a school but causing no casualties. The Russian Ministry of Defence said that it had forced back "nationalists" who had launched the cross-border attacks in Belgorod Oblast back into Ukraine, adding that its forces had killed more than 70 "Ukrainian terrorists" and destroyed four armored combat vehicles and five pickups. The Governor of Russia's Kursk Oblast said three villages bordering Ukraine were left without power after a drone dropped explosives on an electrical substation. Ukraine accused Russia of blocking access to the port of Pivdennyi to grain exports despite the resumption of the Black Sea Grain Initiative.
==== Enzymatic ==== The enzymes traditionally used to digest heparin or HS are naturally produced by the soil bacterium Pedobacter heparinus (formerly named Flavobacterium heparinum). This bacterium is capable of using either heparin or HS as its sole carbon and nitrogen source. To do so, it produces a range of enzymes such as lyases, glucuronidases, sulfoesterases, and sulfamidases. The lyases have mainly been used in heparin/HS studies. The bacterium produces three lyases, heparinases I (EC 4.2.2.7), II (no EC number assigned) and III (EC 4.2.2.8) and each has distinct substrate specificities as detailed below.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.